SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-528593"
 

Search: onr:"swepub:oai:DiVA.org:uu-528593" > Gene expression and...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Leich, E.Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Inst Pathol, Wurzburg, Germany. (author)

Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • Taylor & Francis,2023
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-528593
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-528593URI
  • https://doi.org/10.1080/10428194.2023.2240462DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:153628110URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The Nordic Lymphoma Study Group has performed two randomized clinical trials with chemotherapy-free first-line treatment (rituximab +/- interferon) in follicular lymphoma (FL), with 73% of patients alive and 38% without any need of chemotherapy after 10.6 years median follow-up. In order to identify predictive markers, that may also serve as therapeutic targets, gene expression- and copy number profiles were obtained from 97 FL patients using whole genome microarrays. Copy number alterations (CNAs) were identified, e.g. by GISTIC. Cox Lasso Regression and Lasso logistic regression were used to determine molecular features predictive of time to next therapy (TTNT). A few molecular changes were associated with TTNT (e.g. increased expression of INPP5B, gains in 12q23/q24), but were not significant after adjusting for multiple testing. Our findings suggest that there are no strong determinants of patient outcome with respect to GE data and CNAs in FL patients treated with a chemotherapy-free regimen (i.e. rituximab +/- interferon).

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Brodtkorb, MarianneOslo Univ Hosp, Dept Oncol, Oslo, Norway. (author)
  • Schmidt, T.Univ Regensburg, Inst Funct Genom, Stat Bioinformat, Regensburg, Germany. (author)
  • Altenbuchinger, M.Univ Regensburg, Inst Funct Genom, Stat Bioinformat, Regensburg, Germany.;Univ Med Ctr Gottingen, Dept Med Bioinformat, Gottingen, Germany. (author)
  • Lingjaerde, Ole ChristianUniv Oslo, Dept Comp Sci, Div Biomed Informat, N-0316 Oslo, Norway. (author)
  • Lockmer, S.Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm, Sweden. (author)
  • Holte, H.Oslo Univ Hosp, Dept Oncol, Oslo, Norway. (author)
  • Nedeva, T.Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Inst Pathol, Wurzburg, Germany. (author)
  • Grieb, T.Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Inst Pathol, Wurzburg, Germany. (author)
  • Sander, B.Karolinska Institutet,Karolinska Inst, Dept Lab Med, Div Pathol, Stockholm, Sweden. (author)
  • Sundström, ChristerUppsala universitet,Cancerimmunterapi(Swepub:uu)chrisund (author)
  • Spang, R.Univ Regensburg, Inst Funct Genom, Stat Bioinformat, Regensburg, Germany. (author)
  • Kimby, E.Karolinska Inst, Dept Med Huddinge, Div Hematol, Stockholm, Sweden. (author)
  • Rosenwald, A.Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Inst Pathol, Wurzburg, Germany.;Univ Wurzburg, Inst Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany. (author)
  • Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Inst Pathol, Wurzburg, Germany.Oslo Univ Hosp, Dept Oncol, Oslo, Norway. (creator_code:org_t)

Related titles

  • In:Leukemia and Lymphoma: Taylor & Francis64:12, s. 1927-19371042-81941029-2403

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view